Evaluation of Changes in Choroidal Neovascularization Secondary to Age-related Macular Degeneration after Anti-VEGF Therapy Using Spectral Domain Optical Coherence Tomography

REFERENCES

• Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology. 2001;108:2347–2357.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933–943.
   PubMed Web of Science ®Google Scholar
• Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855–868.
   PubMed Web of Science ®Google Scholar
• Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393–403.
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929–1934.
   PubMed Web of Science ®Google Scholar
• Otani A, Takagi H, Oh H et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64:162–169.
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Brown DM, Zhang K et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–857.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
   PubMed Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–248.
   PubMed Web of Science ®Google Scholar
• Keane PA, Liakopoulos S, Ongchin SC et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3115–3120.
   PubMed Web of Science ®Google Scholar
• Golbaz I, Ahlers C, Schütze C et al. Influence of antiangiogenetic therapy on retinal thickness values in age-related macular degeneration. Ophthalmologe. 2009;106:1103–1110.
   PubMed Web of Science ®Google Scholar
• Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol. 2009;147:831–837.
   PubMed Web of Science ®Google Scholar
• Keane PA, Bhatti RA, Brubaker JW, Liakopoulos S, Sadda SR, Walsh AC. Comparison of clinically relevant findings from high-speed fourier-domain and conventional time-domain optical coherence tomography. Am J Ophthalmol. 2009;148:242–248.e1.
   PubMed Web of Science ®Google Scholar
• Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology. 2009;116:947–955.
   PubMed Web of Science ®Google Scholar
• Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci. 2009;50:2376–2383.
   PubMed Web of Science ®Google Scholar
• Framme C, Walter A, Prahs P et al. Structural changes of the retina after conventional laser photocoagulation and selective retina treatment (SRT) in spectral domain OCT. Curr Eye Res. 2009;34:568–579.
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Stroux A, Wehner A, Heimann H, Foerster MH. Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV. Graefes Arch Clin Exp Ophthalmol. 2005;243:438–445.
   PubMed Web of Science ®Google Scholar
• Ueno C, Emi K, Sato T et al. Efficacy of intravitreal bevacizumab for age-related macular degeneration. Nippon Ganka Gakkai Zasshi. 2010;114:983–988.
   PubMedGoogle Scholar
• Bolz M, Ritter M, Polak K et al. The role of Stratus OCT in anti-VEGF therapy. Qualitative and quantitative assessment of neovascular AMD. Ophthalmologe. 2008;105:650–655.
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168:2036–2053.
   PubMed Web of Science ®Google Scholar
• Framme C, Panagakis G, Birngruber R. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;51:1671–1676.
   PubMedGoogle Scholar
• , The CATT research GroupMartin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL and Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908
   PubMed Web of Science ®Google Scholar
• Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci. 2003;44:2141–2146.
   PubMed Web of Science ®Google Scholar
• Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249–256.
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868–1875.
   PubMed Web of Science ®Google Scholar